| Literature DB >> 31728347 |
Wiwiet Nurwidya Hening1, Ratu Ayu Dewi Sartika2, Rani Sauriasari1.
Abstract
OBJECTIVE: In Indonesia, the role of a hospital pharmacist in pharmaceutical care is still limited or even absent. This study aimed to determine whether counseling by a pharmacist could improve medication adherence, controlling the glycemic status, lipid profile, and blood pressure of type 2 diabetes mellitus (T2DM) outpatients.Entities:
Keywords: Clinical outcomes; Indonesia; diabetic patient; hospital pharmacist; medication adherence
Year: 2019 PMID: 31728347 PMCID: PMC6830025 DOI: 10.4103/jrpp.JRPP_19_67
Source DB: PubMed Journal: J Res Pharm Pract ISSN: 2279-042X
Figure 1Flowchart of participants selected for this study
Baseline demographic and clinical characteristics
| Characteristics | IG ( | CG ( | Total ( | |
|---|---|---|---|---|
| Age (years) | ||||
| 20-40 | 0 | 4 (10.5) | 4 (5.2) | 0.109a |
| 41-60 | 21 (53.8) | 17 (44.7) | 38 (49.4) | |
| >60 | 18 (46.2) | 17 (44.7) | 35 (45.5) | |
| Sex | ||||
| Male | 11 (28.2) | 18 (47.4) | 29 (37.7) | 0.134a |
| Female | 39 (71.8) | 20 (52.6) | 48 (62.3) | |
| Level of education | ||||
| None | 5 (12.8) | 2 (5.3) | 7 (9.1) | 0.514a |
| Primary | 11 (28.2) | 7 (18.4) | 18 (23.4) | |
| Secondary | 18 (46.2) | 24 (63.1) | 42 (54.6) | |
| Bachelor and above | 5 (12.8) | 5 (13.2) | 10 (13.0) | |
| Working status | ||||
| No | 11 (28.2) | 9 (23.7) | 20 (26.0) | - |
| Yes | 5 (12.9) | 12 (31.6) | 17 (22.1) | |
| Homemaker | 23 (59.0) | 17 (44.7) | 40 (51.9) | |
| Smoking | ||||
| Yes | 4 (10.3) | 4 (10.5) | 8 (10.4) | 0.687a |
| No | 35 (89.7) | 34 (89.5) | 69 (89.1) | |
| Exercise | ||||
| Yes | 23 (59.0) | 12 (31.6) | 35 (45.5) | 0.029a,* |
| No | 16 (41.0) | 26 (68.4) | 42 (54.5) | |
| Risk food consumption | ||||
| Not often | 16 (41.0) | 12 (31.6) | 28 (36.4) | 0.532a |
| Often | 23 (59.0) | 26 (68.4) | 49 (63.6) | |
| Duration of DM drug use (months) | ||||
| <12 | 5 (12.8) | 0 (0.0) | 5 (6.5) | 0.990a |
| 12-24 | 11 (28.2) | 2 (5.3) | 13 (16.9) | |
| >24 | 23 (59.0) | 36 (94.7) | 59 (76.6) | |
| Number of DM drugs | ||||
| Single drug | 4 (10.3) | 7 (18.4) | 11 (14.3) | 0.470a |
| Combination of two drugs | 19 (48.7) | 17 (44.7) | 36 (46.8) | |
| Combination of >2 drugs | 16 (41.0) | 14 (36.9) | 30 (38.9) | |
| Type of medicine | ||||
| Oral antidiabetic | 37 (94.9) | 7 (18.4) | 44 (57.1) | <0.0001a,* |
| Insulin injection | 0 (0.0) | 17 (44.7) | 17 (22.1) | |
| Combination | 2 (5.1) | 14 (36.8) | 16 (20.8) | |
| Complications | ||||
| Yes | 23 (59.0) | 23 (60.5) | 46 (59.7) | 1.000a |
| No | 16 (41.0) | 15 (39.5) | 31 (40.3) | |
| Family history of DM | ||||
| Yes | 23 (59.0) | 19 (50.0) | 42 (54.5) | 0.496a |
| No | 16 (41.0) | 19 (50.0) | 35 (45.5) | |
| BMI | 25.90±4.47 | 25.10±3.66 | 25.50±4.09 | 0.396b |
*P value based on Chi-square test. aChi-squared test, bMann-Whitney test. Data were expressed in n (%) or mean±SD. P=Significance of different tests, SD=Standard deviation, BMI=Body mass index, DM=Diabetes mellitus, CG=Control group, IG=Intervention group
Comparison of clinical parameters in both groups
| Variable | IG ( | CG ( | ||||||
|---|---|---|---|---|---|---|---|---|
| Pretest | Posttest | Pretest | Posttest | |||||
| FBG (mg/dL) | 122.64±37.98 | 124.05±49.90 | 0.485 | 175.97±84.4 | 172.89±80.9 | 0.788 | 0.003* | 0.002* |
| PPBG (mg/dL) | 192.56±72.40 | 192.13±88.09 | 0.976 | 232.82±110.2 | 240.45±99.87 | 0.643 | 0.061 | 0.027* |
| HbA1c (%) | 7.29±1.35 | 6.90±1.07 | 0.003* | 9.07±2.06 | 8.85±2.00 | 0.318 | <0.0001* | <0.0001* |
| TC (mg/dL) | 230.15±57.02 | 198.72±45.66 | 0.002* | 207.24±38.41 | 198.687±40.97 | 0.177 | 0.093 | 0.997 |
| HDL-c (mg/dL) | 45.187±12.23 | 51.72±13.16 | 0.004* | 48.97±11.23 | 52.26±16.42 | 0.166 | 0.161 | 0.873 |
| LDL-c (mg/dL) | 132.82±59.46 | 110.41±40.56 | 0.026* | 112.58±55.32 | 112.13±38.23 | 0.37 | 0.126 | 0.691 |
| TG (mg/dL) | 221.05±192.5 | 164.15±102.9 | 0.012* | 185.66±132.8 | 163.08±116.4 | 0.157 | 0.169 | 0.628 |
| SBP (mmHg) | 123.59±12.24 | 122.82±14.31 | 0.469 | 122.63±9.78 | 121.32±10.44 | 0.286 | 0.924 | 0.871 |
| DBP (mmHg) | 78.72±6.95 | 75.38±6.82 | 0.059 | 78.687±6.64 | 78.16±5.12 | 0.669 | 0.761 | 0.071 |
| Adherence | 0.79±0.128 | 0.44±0.088 | 0.006* | 0.84±0.128 | 1.13±0.132 | 0.008* | 0.743 | <0.0001* |
*P value based on T-test. Data presented as mean±SD. aBefore versus after intervention on IG, bBefore versus after intervention on CG, cIG versus CG before intervention, dIG versus CG after intervention. CG=Control group, DBP=Diastolic blood pressure, FBG=Fasting blood glucose, HbA1c=Glycosylated hemoglobin A1,HDL-c=High-density lipoprotein-cholesterol, IG=Intervention group, LDL-c=Low-density lipoprotein-cholesterol, SBP=Systolic blood pressure, SD=Standard deviation, TG=Triglyceride, TC=Total cholesterol, PPBG=Postprandial blood glucose
Clinical outcomes in category
| Clinical parameters | Pretest | Posttest | ||||
|---|---|---|---|---|---|---|
| Controlled | Uncontrolled | Controlled | Uncontrolled | |||
| FBG | ||||||
| IG | 25 (64.1) | 14 (35.9) | 0.03* | 23 (59.0) | 16 (41.0) | 0.051* |
| CG | 14 (36.8) | 24 (63.2) | 13 (34.2) | 25 (65.8) | ||
| PPBG | ||||||
| IG | 23 (59.0) | 16 (41.0) | 0.21 | 22 (54.6) | 17 (43.6) | 0.304 |
| CG | 16 (41.2) | 22 (57.9) | 16 (42.1) | 22 (57.9) | ||
| HbA1c | ||||||
| IG | 22 (56.4) | 17 (43.6) | 0.003* | 27 (69.2) | 12 (30.8) | <0.0001* |
| CG | 8 (21.1) | 30 (78.9) | 7 (18.4) | 31 (81.6) | ||
| TC | ||||||
| IG | 13 (33.3) | 26 (66.7) | 0.428 | 20 (51.3) | 19 (48.7) | 0.411 |
| CG | 17 (44.7) | 21 (55.3) | 24 (63.2) | 14 (36.8) | ||
| HDL-c | ||||||
| IG | 26 (66.7) | 13 (33.3) | 0.493 | 32 (82.1) | 7 (17.9) | 0.734 |
| CG | 29 (76.3) | 9 (23.7) | 29 (76.3) | 9 (23.7) | ||
| LDL-c | ||||||
| IG | 11 (28.2) | 28 (71.8) | 0.747 | 14 (35.9) | 25 (64.1) | 0.643 |
| CG | 13 (34.2) | 25 (62.8) | 11 (28.9) | 27 (71.1) | ||
| TG | ||||||
| IG | 19 (48.7) | 20 (51.3) | 0.908 | 21 (53.8) | 18 (46.2) | 0.55 |
| CG | 20 (52.6) | 18 (47.4) | 24 (63.2) | 14 (36.8) | ||
| SBP | ||||||
| IG | 23 (59.0) | 16 (41.0) | 0.574 | 26 (66.7) | 13 (33.3) | 0.493 |
| CG | 19 (50.0) | 19 (50.0) | 29 (76.3) | 9 (23.7) | ||
| DBP | ||||||
| IG | 34 (87.2) | 5 (12.8) | 0.963 | 38 (97.4) | 1 (2.6) | 0.982 |
| CG | 32 (84.2) | 6 (15.8) | 36 (94.7) | 2 (5.3) | ||
*P value based on Chi-square test. Data were expressed in n (%). CG=Control group, DBP=Diastolic blood pressure, FBG=Fasting blood glucose, HbA1c=Glycosylated hemoglobin A1, HDL-c=High-density lipoprotein-cholesterol, IG=Intervention group, LDL-c=Low-density lipoprotein-cholesterol, SBP=Systolic blood pressure, TG=Triglyceride, TC=Total cholesterol, PPBG=Postprandial blood glucose
Multiple regression analysis on the influencing factors of fasting blood glucose and glycated hemoglobin
| Variable | Type of OR | OR | 95% CI | ||
|---|---|---|---|---|---|
| Lower | Upper | ||||
| FBG | |||||
| Model 1 | |||||
| Counseling | Crude OR | 2.764 | 1.096 | 6.974 | 0.031* |
| Model 2 | |||||
| Counseling | Adjusted OR | 2.062 | 0.603 | 7.059 | 0.249 |
| Type of medicine | 1.319 | 0.605 | 2.879 | 0.486 | |
| HbA1c | |||||
| Model 1 | |||||
| Counseling | Crude OR | 9.964 | 3.434 | 28.917 | <0.0001* |
| Model 2 | |||||
| Counseling | Adjusted OR | 2.247 | 0.51 | 9.889 | 0.284 |
| Type of medicine | 3.252 | 1.281 | 9.706 | 0.015 | |
| Duration of DM drug use | 1.302 | 0.475 | 3.571 | 0.608 | |
| Medication adherence | 2.737 | 0.786 | 9.538 | 0.114 | |
| Age | 0.559 | 0.187 | 1.672 | 0.298 | |
| Model 3 | |||||
| Counseling | Adjusted OR | 3.516 | 0.880 | 14.045 | 0.075 |
| Type of medicine | 2.973 | 1.085 | 8.147 | 0.034* | |
| Duration of DM drug use | 1.152 | 0.442 | 3.002 | 0.772 | |
*P value based on Binomial logistic regression test. FBG=Fasting blood glucose, HbA1c=Glycated hemoglobin, OR=Odds ratio, CI=Confidence interval, DM=Diabetes mellitus